Core Insights - TC BioPharm has successfully dosed a total of 6 patients in the ACHIEVE Phase 2b trial, with 5 new patients receiving their first dose at a higher dose level [1][2] - The trial involves administering up to 1 billion gamma delta T cells over four doses, with each 5mL dose containing up to 230 million cells [2] - The company has reported strong patient recruitment and retention rates, indicating significant clinician interest in TCB008 as a monotherapy for blood cancers [3] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment, specifically acute myeloid leukemia [5][6] - The company is recognized as a leader in this field and is the first to conduct Phase II/pivotal clinical studies in oncology using its proprietary allogeneic CryoTC technology [6] - Gamma-delta T cells are immune cells that can differentiate between healthy and diseased tissue, embodying properties of both the innate and adaptive immune systems [5]
TCBP Announces Dosing of 5 New Patients in ACHIEVE